Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the European Medicines Agency (EMA) has accepted for
review a Marketing Authorization Application (MAA) for pembrolizumab
(MK-3475), the company’s investigational anti-PD-1 antibody, for the
treatment of advanced melanoma.
for Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma investment picks